Hostname: page-component-cb9f654ff-d5ftd Total loading time: 0 Render date: 2025-08-06T08:21:51.310Z Has data issue: false hasContentIssue false
  • English
  • Français

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

Published online by Cambridge University Press:  16 April 2020

Robert A. Lasser ,
Cynthia A. Bossie ,
Georges M. Gharabawi  and
Martin Turner
Robert A. Lasser*
Affiliation:
Janssen Medical Affairs, LLC 1125 Trenton-Harbourton Road, Office A20904, Titusville, NJ 08560-0200, USA
Cynthia A. Bossie
Affiliation:
Janssen Medical Affairs, LLC 1125 Trenton-Harbourton Road, Office A20904, Titusville, NJ 08560-0200, USA
Georges M. Gharabawi
Affiliation:
Janssen Medical Affairs, LLC 1125 Trenton-Harbourton Road, Office A20904, Titusville, NJ 08560-0200, USA
Martin Turner
Affiliation:
NHS Greater Glasgow, Larkfield Centre, Lenzie, Glasgow, UK
*
*Corresponding author. rlasser@janus.jnj.com (R.A. Lasser).
Get access

Abstract

Background

Conventional depot antipsychotics can provide constant pharmacologic treatment, eliminating partial compliance and reducing relapse risk. Atypical antipsychotics, have improved clinical profiles but require daily dosing, compromising their overall effectiveness. As oral risperidone provides safety and efficacy benefits over oral haloperidol, improvements may be realized by replacing conventional with atypical agents in long-acting therapy. This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics.

Methods

A multi-center, open-label study enrolled 725 patients with schizophrenia or schizoaffective disorder, judged clinically stable and maintained on stable antipsychotic doses for ≥4 weeks. Assignment by clinician judgment to receive 25–75 mg of long-acting risperidone every 2 weeks for 50 weeks followed, with performance of standard safety and efficacy assessments. Data are presented on patients receiving conventional depot antipsychotic monotherapy at study entry.

Results

In the 188 (25.9%) patients receiving conventional depot antipsychotic monotherapy at entry, mild-to-moderate mean (±S.D.) Positive and Negative Syndrome Scale (PANSS)-total scores improved significantly after receiving long-acting risperidone (64.2 ± 18.9 to 58.2 ± 20.3; P < 0.001). Clinical improvement of ≥20%, 40%, or 60% reduction in PANSS-total score, occurred in 52%, 34%, and 16% of patients, respectively. ESRS subjective ratings and objective physician ratings (Parkinsonism) decreased significantly (P < 0.001).

Conclusion

Stable patients with mild, residual symptomatology treated with conventional depot antipsychotics experienced significant improvement in psychiatric and movement disorder symptomatology following 1-year of treatment with long-acting risperidone.

Keywords

AntipsychoticConventionalDepotLong-actingMicrospheresPharmacotherapyRisperidoneSchizoaffectiveSchizophrenia

Information

Type
Original article
Information
European Psychiatry , Volume 19 , Issue 4 , June 2004 , pp. 219 - 225
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Weiden, PZygmunt, A.Medication noncompliance in schizophrenia. J Pract Psychiatry Behav Health 1997;3:106–10.Google Scholar
Dencker, SJ.The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984;45:22–7.Google ScholarPubMed
Kane, JMAguglia, EAltamura, ACet al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55–66.CrossRefGoogle Scholar
Kane, JM.Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396–408.CrossRefGoogle ScholarPubMed
Babiker, IE.Comparative efficacy of long-acting depot and oral neu-roleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987;48:94–7.Google ScholarPubMed
Davis, JMMatalon, LWatanabe, MDBlake, L.Depot antipsychotic drugs: place in therapy. Drugs 1994;47(5):741–73.CrossRefGoogle ScholarPubMed
Masand, PSBerry, SL.Switching antipsychotic therapies. Ann Phar-macother 2000;34:200–7.CrossRefGoogle ScholarPubMed
Kane, JM.Extrapyramidal side effects are unacceptable. Eur Neurop-sychopharmacol 2001;11(Suppl 4):S397–403.CrossRefGoogle ScholarPubMed
Csernansky, JGMahmoud, RBrenner, R.A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med 2002;346:16–22.CrossRefGoogle ScholarPubMed
Dolder, CRLacro, JPDunn, LBJeste, DV.Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103–8.CrossRefGoogle Scholar
Mahmoud, RAEnglehart, MOster, Get al. Risperidone vs. conven tional antipsychotics: a prospective randomized naturalistic effective ness trial on outcomes in chronic schizophrenia. 36th Annual Meeting of the ACNP, Kamuela, Hawaii. 1997.Google Scholar
Kane, JMEerdekens, MLindenmayer, J-Pet al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–32.Google ScholarPubMed
Fleischhacker, WWEerdekens, MKarcher, Ket al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsy-chotic. J Clin Psychiatry 2003;64:1250–7.CrossRefGoogle Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA; 1994.Google Scholar
Clinical Global Impressions. In: Guy, W editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Department of Health, Education, and Welfare; 1976. p. 218–20 Revised. DHEW Pub. No. (ADM) 76.Google Scholar
Kay, SRFiszbein, AOpler, LA.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.CrossRefGoogle Scholar
Marder, SRDavis, JMChouinard, G.The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58: 538–46.CrossRefGoogle ScholarPubMed
Chouinard, GRoss-Chouinard, AAnnable, LJones, BD.Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.Google Scholar
Desai, NMHuq, AMartin, SDet al. Switching from depot antipsy-choticsto risperidone: results of a study of chronic schizophrenia. Adv Ther 1999;16:78–88.Google ScholarPubMed
Marder, SRMeibach, RC.Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–35.Google ScholarPubMed
Davis, JChen, N.Clinical profile of an atypical antipsychotic: risperi-done. Schizophr Bull 2002;28(1):43–61.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.